Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

OncoImmunology

Volumn 5, Issue 10, 2016, Pages

  Kleinpeter, Patricia ^a   Fend, Laetitia ^a,b   Thioudellet, Christine ^a   Geist, Michel ^a   Sfrontato, Nathalie ^a   Koerper, Véronique ^a   Fahrner, Catherine ^a   Schmitt, Doris ^a   Gantzer, Murielle ^a   Remy Ziller, Christelle ^a   Brandely, Renée ^a   Villeval, Dominique ^a   Rittner, Karola ^a   Silvestre, Nathalie ^a   Erbs, Philippe ^a   Zitvogel, Laurence ^b,c,d,e   Quéméneur, Eric ^a   Préville, Xavier ^a,f   Marchand, Jean Baptiste ^a  

^a TRANSGENE S A   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c University Paris XI   (France)

^d GRCC   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f Firalis Group   (France)

Author keywords

Monoclonal antibody; oncolytic virotherapy; PD 1; vaccinia virus; vectorization

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INFILTRATION; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNOMODULATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; SIZE EXCLUSION CHROMATOGRAPHY; TUMOR MICROENVIRONMENT; VACCINIA VIRUS;

EID: 84991037820     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1220467     Document Type: Article

References (28)

1. J.Pol, N.Bloy, F.Obrist, A.Eggermont, J.Galon, I.Cremer, P.Erbs, J.M.Limacher, X.Preville, L.Zitvogel et al. Trial Watch::Oncolytic viruses for cancer therapy. Oncoimmunology 2014; 3:e28694; PMID:25097804; http://dx.doi.org/10.4161/onci.28694
2. R.H.Andtbacka, H.L.Kaufman, F.Collichio, T.Amatruda, N.Senzer, J.Chesney, K.A.Delman, L.E.Spitler, I.Puzanov, S.S.Agarwala et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J clin Oncol 2015; 33:2780-8; PMID:26014293; http://dx.doi.org/10.1200/JCO.2014.58.3377
3. M.Lusky, P.Erbs, J.Foloppe, R.B.Acres. Oncolytic vaccinia virus:a silver bullet? Exp Rev Vaccines 2010; 9:1353-6; PMID:21105770; http://dx.doi.org/10.1586/erv.10.137
4. W.M.Chan, G.McFadden. Oncolytic poxviruses. Annu Rev Virol 2014; 1:119-41; PMID:25839047; http://dx.doi.org/10.1146/annurev-virology-031413-085442
5. P.Erbs, E.Regulier, J.Kintz, P.Leroy, Y.Poitevin, F.Exinger, R.Jund, M.Mehtali. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60:3813-22; PMID:10919655
6. J.Foloppe, J.Kintz, N.Futin, A.Findeli, P.Cordier, Y.Schlesinger, C.Hoffmann, C.Tosch, J.M.Balloul, P.Erbs. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 2008; 15:1361-71; PMID:18480846; http://dx.doi.org/10.1038/gt.2008.82
7. K.A.Parato, C.J.Breitbach, F.Le Boeuf, J.Wang, C.Storbeck, C.Ilkow, J.S.Diallo, T.Falls, J.Burns, V.Garcia et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012; 20:749-58; PMID:22186794; http://dx.doi.org/10.1038/mt.2011.276
8. C.J.Breitbach, R.Arulanandam, N.De Silva, S.H.Thorne, R.Patt, M.Daneshmand, A.Moon, C.Ilkow, J.Burke, T.H.Hwang et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res 2013; 73:1265-75; PMID:23393196; http://dx.doi.org/10.1158/0008-5472.CAN-12-2687
9. D.H.Kirn, S.H.Thorne. Targeted and armed oncolytic poxviruses:a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9:64-71; PMID:19104515; http://dx.doi.org/10.1038/nrc2545
10. A.Sistigu, T.Yamazaki, E.Vacchelli, K.Chaba, D.P.Enot, J.Adam, I.Vitale, A.Goubar, E.E.Baracco, C.Remedios et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20:1301-9; PMID:25344738; http://dx.doi.org/10.1038/nm.3708
11. Z.S.Guo, Z.Liu, D.L.Bartlett. Oncolytic Immunotherapy:Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Front Oncol 2014; 4:74; PMID:24782985; http://dx.doi.org/10.3389/fonc.2014.00074
12. L.B.John, L.J.Howland, J.K.Flynn, A.C.West, C.Devaud, C.P.Duong, T.J.Stewart, J.A.Westwood, Z.S.Guo, D.L.Bartlett et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res 2012; 72:1651-60; PMID:22315352; http://dx.doi.org/10.1158/0008-5472.CAN-11-2788
13. J.Rojas, P.Sampath, W.Hou, S.H.Thorne. Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. Clin Cancer Res 2015. 24:5543-51; PMID:26187615; http://dx.doi.org/10.1158/1078-0432.CCR-14-2009
14. H.Khan, R.Gucalp, I.Shapira. Evolving concepts:immunity in oncology from targets to treatments. J Oncol 2015; 2015:847383; PMID:26060497; http://dx.doi.org/10.1155/2015/847383
15. S.L.Topalian, C.G.Drake, D.M.Pardoll. Immune checkpoint blockade:a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61; PMID:25858804; http://dx.doi.org/10.1016/j.ccell.2015.03.001
16. B.Kaplan, A.Livneh, B.A.Sela. Immunoglobulin free light chain dimers in human diseases. Scient World J 2011; 11:726-35; PMID:21442150; http://dx.doi.org/10.1100/tsw.2011.65
17. C.Li, A.Rossomando, S.L.Wu, B.L.Karger. Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches. mAbs 2013; 5:565-75; PMID:23751726; http://dx.doi.org/10.4161/mabs.24814
18. M.J.Ansari, A.D.Salama, T.Chitnis, R.N.Smith, H.Yagita, H.Akiba, T.Yamazaki, M.Azuma, H.Iwai, S.J.Khoury et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 198:63-9; PMID:12847137; http://dx.doi.org/10.1084/jem.20022125
19. S.Paul, N.Bizouarne, K.Dott, L.Ruet, P.Dufour, R.B.Acres, M.P.Kieny. Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody. Cancer Gene Ther 2000; 7:615-23; PMID:10811480; http://dx.doi.org/10.1038/sj.cgt.7700161
20. S.Paul, E.Regulier, R.Rooke, F.Stoeckel, M.Geist, H.Homann, J.M.Balloul, D.Villeval, Y.Poitevin, M.P.Kieny et al. Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies. Cancer Gene Ther 2002; 9:470-7; PMID:11961670; http://dx.doi.org/10.1038/sj.cgt.7700461
21. A.Frentzen, Y.A.Yu, N.Chen, Q.Zhang, S.Weibel, V.Raab, A.A.Szalay. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci U S A 2009; 106:12915-20; PMID:19617539; http://dx.doi.org/10.1073/pnas.0900660106
22. C.E.Engeland, C.Grossardt, R.Veinalde, S.Bossow, D.Lutz, J.K.Kaufmann, I.Shevchenko, V.Umansky, D.M.Nettelbeck, W.Weichert et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Thera 2014; 22:1949-59; PMID:25156126; http://dx.doi.org/10.1038/mt.2014.160
23. J.D.Dias, O.Hemminki, I.Diaconu, M.Hirvinen, A.Bonetti, K.Guse, S.Escutenaire, A.Kanerva, S.Pesonen, A.Loskog et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther 2012; 19:988-98; PMID:22071969; http://dx.doi.org/10.1038/gt.2011.176
24. A.Marabelle, H.Kohrt, C.Caux, R.Levy. Intratumoral immunization:a new paradigm for cancer therapy. Clin Cancer Res 2014; 20:1747-56; PMID:24691639; http://dx.doi.org/10.1158/1078-0432.CCR-13-2116
25. A.Marabelle, H.Kohrt, R.Levy. Intratumoral anti-CTLA-4 therapy:enhancing efficacy while avoiding toxicity. Clin Cancer Res 2013; 19:5261-3; PMID:23965900; http://dx.doi.org/10.1158/1078-0432.CCR-13-1923
26. A.Palazon, I.Martinez-Forero, A.Teijeira, A.Morales-Kastresana, C.Alfaro, M.F.Sanmamed, J.L.Perez-Gracia, I.Penuelas, S.Hervas-Stubbs, A.Rouzaut et al. The HIF-1alpha hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Dis 2012; 2:608-23; PMID:22719018; http://dx.doi.org/10.1158/2159-8290.CD-11-0314
27. J.L.Rosel, P.L.Earl, J.P.Weir, B.Moss. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. J Virol 1986; 60:436-49; PMID:3021979
28. M.A.Cochran, C.Puckett, B.Moss. In vitro mutagenesis of the promoter region for a vaccinia virus gene:evidence for tandem early and late regulatory signals. J Virol 1985; 54:30-7; PMID:3973982